567.56 USD
-4.3 (-0.75%)
567.56 USD
0 (0%)
Taking everything into account, MEDP scores 7 out of 10 in our fundamental rating. MEDP was compared to 57 industry peers in the Life Sciences Tools & Services industry. MEDP scores excellent points on both the profitability and health parts. This is a solid base for a good stock. MEDP is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make MEDP a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
MEDP had positive earnings in the past year.
MEDP had a positive operating cash flow in the past year.
Each year in the past 5 years MEDP has been profitable.
In the past 5 years MEDP always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 24.70%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
MEDP has a better Return On Equity (147.46%) than 100.00% of its industry peers.
MEDP has a Return On Invested Capital of 91.45%. This is amongst the best in the industry. MEDP outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MEDP is significantly above the industry average of 13.99%.
The last Return On Invested Capital (91.45%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
With an excellent Profit Margin value of 18.36%, MEDP belongs to the best of the industry, outperforming 92.98% of the companies in the same industry.
In the last couple of years the Profit Margin of MEDP has grown nicely.
MEDP's Operating Margin of 21.50% is amongst the best of the industry. MEDP outperforms 89.47% of its industry peers.
In the last couple of years the Operating Margin of MEDP has grown nicely.
MEDP has a worse Gross Margin (31.11%) than 68.42% of its industry peers.
MEDP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
MEDP has less shares outstanding than it did 5 years ago.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 8.07 indicates that MEDP is not in any danger for bankruptcy at the moment.
The Altman-Z score of MEDP (8.07) is better than 87.72% of its industry peers.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.07 |
ROIC/WACC8.43
WACC10.85%
2.3 Liquidity
A Current Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
With a Current ratio value of 0.57, MEDP is not doing good in the industry: 94.74% of the companies in the same industry are doing better.
MEDP has a Quick Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP has a worse Quick ratio (0.57) than 92.98% of its industry peers.
MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.22% over the past year.
MEDP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 33.22% yearly.
The Revenue has grown by 13.88% in the past year. This is quite good.
MEDP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.62% yearly.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
The Earnings Per Share is expected to grow by 12.31% on average over the next years. This is quite good.
The Revenue is expected to grow by 12.31% on average over the next years. This is quite good.
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
MEDP is valuated quite expensively with a Price/Earnings ratio of 39.69.
MEDP's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 26.59. MEDP is valued slightly more expensive when compared to this.
The Price/Forward Earnings ratio is 33.76, which means the current valuation is very expensive for MEDP.
Based on the Price/Forward Earnings ratio, MEDP is valued a bit cheaper than 64.91% of the companies in the same industry.
MEDP's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.69 | ||
| Fwd PE | 33.76 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as MEDP.
Based on the Price/Free Cash Flow ratio, MEDP is valued cheaply inside the industry as 80.70% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.62 | ||
| EV/EBITDA | 29.55 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
MEDP's earnings are expected to grow with 13.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.03
PEG (5Y)1.19
EPS Next 2Y15.37%
EPS Next 3Y13.97%
5. Dividend
5.1 Amount
MEDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
567.56
-4.3 (-0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.26%
Inst Owner Change-6.93%
Ins Owners0.37%
Ins Owner Change-6.92%
Market Cap15.99B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.22
Price Target550.48 (-3.01%)
Short Float %6.06%
Short Ratio4.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)5.89%
PT rev (3m)27.03%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)11.33%
EPS NY rev (1m)0.03%
EPS NY rev (3m)5.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)1.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.69 | ||
| Fwd PE | 33.76 | ||
| P/S | 6.78 | ||
| P/FCF | 23.62 | ||
| P/OCF | 22.48 | ||
| P/B | 54.45 | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.55 |
EPS(TTM)14.3
EY2.52%
EPS(NY)16.81
Fwd EY2.96%
FCF(TTM)24.02
FCFY4.23%
OCF(TTM)25.25
OCFY4.45%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)2.03
PEG (5Y)1.19
Graham Number57.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 8.07 |
F-Score8
WACC10.85%
ROIC/WACC8.43
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.32%
EBIT Next 3Y15.76%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
What is the valuation status of MEDPACE HOLDINGS INC (MEDP) stock?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
How profitable is MEDPACE HOLDINGS INC (MEDP) stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for MEDP stock?
The Earnings per Share (EPS) of MEDPACE HOLDINGS INC (MEDP) is expected to grow by 19.51% in the next year.